Assisted Reproductive Technologies

Astrid E.P. Cantineau*, Cato J. Vrouwenraets, Aafke P.A. van Montfoort

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademic

Abstract

Since the birth of Louise Brown, the first “test tube baby, " in 1978, assisted reproductive technology (ART) has been widely implemented as a standard treatment for couples with subfertility problems. An estimated 8 million children have been born via ART worldwide and up to 6% of newborns in Europe and 1.5% in United States are conceived via this technique [2]. ART pregnancies are at an increased risk for neonatal complications such as preterm birth and low birth weight as well as maternal complications such as gestational diabetes and preeclampsia. The exact mechanism behind the adverse outcomes is not known, but a role for the placenta is likely. In this chapter we will summarize current knowledge on human placenta development and functioning in relation to ART treatments. We will focus on morphology, vascularization, immunology, placental biomarkers, and aneuploidies.
Original languageEnglish
Title of host publicationBenirschke’s Pathology of the Human Placenta: Seventh Edition
EditorsRebecca N. Baergen, Graham J. Burton, Cynthia G. Kaplan
PublisherSpringer International Publishing
Pages887-900
Number of pages14
Edition7
ISBN (Electronic)9783030847258
ISBN (Print)9783030847241
DOIs
Publication statusPublished - 1 Jan 2021

Keywords

  • ART
  • Confined placental mosaicism
  • Frozen embryo transfer
  • Oocyte donation
  • Placenta immunology
  • Placental biomarkers
  • Placental metabolism
  • Placental vascularization

Cite this